Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study

Background: Women with unilateral breast cancer (UBC) are at risk of developing a subsequent contralateral breast cancer (CBC). Common variants are associated with breast cancer risk. Whether these influence CBC risk is unknown. Methods: Participants were breast cancer cases from the population-based Women’s Environmental Cancer and Radiation Epidemiology (WECARE) Study. Sixty-seven established breast cancer risk loci were genotyped directly or by imputation in 1459 case subjects with CBC and 2126 UBC control subjects. An unweighted polygenic risk score (PRS) was created by summing the number of risk alleles for each directly genotyped single nucleotide polymorphism (SNP), or for imputed loci, the imputed dosage. A weighted PRS was calculated similarly, but where each SNP’s contribution was weighted by the published per-allele log odds ratio. Unweighted and weighted polygenic risk scores and CBC risk were modeled using conditional logistic regression. Cumulative CBC risk was estimated and benchmarked using Surveillance, Epidemiology, and End Results population incidence rates. Results: Both unweighted and weighted PRS were statistically significantly associated with CBC risk. The adjusted risk ratio of CBC in women in the upper quartile of unweighted PRS compared with the lowest quartile was 1.63 (95% confidence interval [CI] = 1.33 to 2.00). The estimated 10-year cumulative risk for women in the upper quartile of the unweighted PRS was 7.4% (95% CI = 6.0% to 9.1%). For women in the upper quartile of the weighted PRS, the risk ratio for CBC was 1.75 (95% CI = 1.41 to 2.18) compared with women in the lowest quartile. There was no statistically significant heterogeneity by age, treatment (radiation therapy dose, tamoxifen, chemotherapy), estrogen receptor status of the first primary, histology of the first primary, length of at-risk period for CBC, or breast cancer family history. Conclusions: Common genomic variants associated with the development of first primary breast cancer are also associated with the development of CBC; the risk is strongest among those who carry more risk alleles.

[1]  Jane E. Carpenter,et al.  PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS , 2016, Journal of Medical Genetics.

[2]  Jane E. Carpenter,et al.  Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants , 2015, JNCI Journal of the National Cancer Institute.

[3]  Patrick Neven,et al.  Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer , 2015 .

[4]  M. Pollán,et al.  Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. , 2014, Breast.

[5]  R. Weigel,et al.  Review of risk factors for the development of contralateral breast cancer. , 2013, American journal of surgery.

[6]  Karen R. Sepucha,et al.  Perceptions, Knowledge, and Satisfaction With Contralateral Prophylactic Mastectomy Among Young Women With Breast Cancer , 2013, Annals of Internal Medicine.

[7]  Jaana M. Hartikainen,et al.  Large-scale genotyping identifies 41 new loci associated with breast cancer risk , 2013, Nature Genetics.

[8]  Jennifer D. Brooks,et al.  Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Cross,et al.  CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Begg,et al.  Rare germline mutations in PALB2 and breast cancer risk: A population‐based study , 2012, Human mutation.

[11]  D. Duggan,et al.  Single nucleotide polymorphisms associated with risk for contralateral breast cancer in the Women's Environment, Cancer, and Radiation Epidemiology (WECARE) Study , 2011, Breast Cancer Research.

[12]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[13]  A. Stewart,et al.  Trends in Contralateral Prophylactic Mastectomy for Unilateral Cancer: A Report From the National Cancer Data Base, 1998–2007 , 2010, Annals of Surgical Oncology.

[14]  Hoda Anton-Culver,et al.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  C. Begg,et al.  Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: results from the WECARE study , 2010, Cancer Causes & Control.

[16]  Alun Thomas,et al.  Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. , 2009, American journal of human genetics.

[17]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[18]  A. Børresen-Dale,et al.  Variants in the ATM gene associated with a reduced risk of contralateral breast cancer. , 2008, Cancer research.

[19]  A. Børresen-Dale,et al.  Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study , 2008, British Journal of Cancer.

[20]  T. Tuttle,et al.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[22]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[23]  Bryan Langholz,et al.  Study design: Evaluating gene–environment interactions in the etiology of breast cancer – the WECARE study , 2004, Breast Cancer Research.

[24]  A. Børresen-Dale,et al.  Designing and implementing quality control for multi‐center screening of mutations in the ATM gene among women with breast cancer , 2003, Human mutation.

[25]  W. Thompson,et al.  Epidemiology of contralateral breast cancer. , 1999, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[26]  Jane E. Carpenter,et al.  PALB2,CHEK2 and ATM rare variants and cancer risk: Data from COGS , 2016 .

[27]  C. Melissa,et al.  CHEK2 and ATM rare variants and cancer risk: data from COGS. , 2016 .

[28]  A. Børresen-Dale,et al.  Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. , 2010, Journal of the National Cancer Institute.